Elizabeth H.Z. Thompson, Ph.D., is leaving her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals Inc. Effective October 23, 2026, Dr. Thompson will no longer serve as an employee of the company or hold her former executive position. She informed the company of her planned retirement for personal reasons on April 27, 2026, a move previously disclosed in a Form 8-K filed with the Securities and Exchange Commission on May 1, 2026.
Although Dr. Thompson is stepping down from her executive role, she will remain affiliated with Acadia Pharmaceuticals. Effective October 23, 2026, the company will retain her as a consultant. She intends to provide limited consulting services through December 31, 2026. The company is currently in the process of identifying a replacement for Dr. Thompson's role as Head of Research and Development.
Acadia Pharmaceuticals Inc. is incorporated in Delaware and has its principal executive offices in San Diego, California. The company's common stock trades on The Nasdaq Stock Market LLC under the ticker symbol ACAD. The Form 8-K report was signed by Jennifer J. Rhodes, Executive Vice President and Chief Legal Officer, on October 23, 2026.
The filing notes that the report contains forward-looking statements regarding Dr. Thompson's continued service as a consultant and the company's search for a successor. These statements are based on the company's expectations and assumptions as of the filing date. Actual results may differ due to risks and uncertainties, including the possibility that Dr. Thompson may decide not to serve as a consultant. The company states it assumes no obligation to update these forward-looking statements unless required by law.